Clinical trial
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of…
NCT00165633 · Eisai Limited, Industry · Terminated
Key facts
| NCT number | NCT00165633 |
|---|---|
| Title | A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma |
| Official title | A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma |
| Lead sponsor | Eisai Limited, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Menatetrenone, Placebo |
| Enrollment | 540 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 9, 2008 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: